Schwab Network 对 $LLY 的判断变化

频道资料 →频道引用的来源:BFA and JP Morgan、Baird、Bank of America、Barclays、Berenberg、Bernstein、Bernstein, with a Jefferies target cut noted、Bilal Little、Bird (analyst firm)、CEO、CEO Joe Dominguez、Caner、Citi、Citigroup、Citizens、Daiwa、Dan Deming and Michael Monahan、Dan Ies; Morgan Stanley、Dan Ives、Dan Ives and unnamed analysts、Deutsche Bank、Erit Research、Evercore ISI、Evercore ISI; Dan Ives、Goldman Sachs、JP Morgan Chase、JPMorgan、JPMorgan Chase、James Demerard of Wall Street Research、Jefferies、Jefferies, UBS and Citigroup、Jensen Huang; Dan Ives、KeyBank、Loop Capital、Mattie Natsson、Michael Saylor、Milius (analyst)、Morgan Stanley、Northrop、Oppenheimer、Oppenheimer, Freedom Broker、Oracle、PFA analysts、Quantum CEO、RBC、Reddit CEO、Rothschild Redburn、SK Hynix、Seth、Tim Bigham、Tim and KG、Truist、UBS、Wall Street Journal、Wedbush、Wells Fargo、analysts、the street共 7 条

Schwab Network 自 2026-09-15 起在 7 个视频里谈过 $LLY,最近一次(2026-11-16)为看涨。

2026-11-16看涨
《Adam Coons On Defense; "No Touch" on NVDA, Avoiding HD and LOW Pre-Earnings》
AI 摘要 · Eli Lilly 具有一定防御性;随着减肥药持续上市,接下来是 Retatrutide/GLP-3,它可能成为一款颠覆格局、消灭竞争的产品。说话者称 LLY 与 Google 一样有 10% 至 20% 的上涨空间,两者可因不同原因、在不同情境下跑赢。

像 Google 这样你喜欢的股票。它财报后确实出现了下跌,但整体处于某种上行趋势。还有 Eli Lily。你认为这两只股票都有 10% 到 20% 的上涨潜力吗?

Share like Google that you liked. I mean, it saw that decline after the earnings, but it was in a somewhat upward trend. And Eli Lily. Do you think both of these stocks have a 10 to 20% upside potential?

至于 Eli Lilly,它同样算是一只偏防御性的股票,但他们推出的产品,以及我们看到各种减肥药不断推出。我相信“Retatrotide”是下一个即将投产的产品。有人称它为“GLP-3”。

这款药很可能成为他们在这个领域的颠覆性产品,并可能淘汰其余竞争对手。

As for Eli Lilly, it is once again a somewhat defensive stock , but the products they are putting forward and we see a continuation of the introduction of various obesity drugs.

I believe "Retatrotide" is next in the production line. Some people call it "GLP-3". This drug is likely to be a game-changer for them in this field, and may eliminate the rest of the competition.

2026-11-13看涨
《PPI Mostly Cool, AI at "Crossroads" Amid NVDA CEO Search》
AI 摘要 · Eli Lilly 是一个高溢价成长故事:在表现出色的一年里上涨35%,也是医疗保健板块上涨行情的领跑者之一;它凭借三款领先的 GLP1 产品抓住了医疗保健领域最大的机会,有利的人口结构持续为强劲的研发管线提供顺风,因此其高溢价估值是合理的。

Eli Lilly 是你名单上的名字之一。我猜这是对 GLP1 领域的押注,但请给我们讲讲你的投资逻辑。正是如此。Eli Lilly 今年表现很好,上涨了35%,确实是这轮医疗保健行情中的领跑者之一。

正如你提到的,他们凭借三款领先的 GLP1 产品,抓住了当前医疗保健领域最大的机会。

Eli Lilly is one of those names on your list. I'm betting this is a bet on the GLP1 space, but walk us through your thesis here. Exactly. You know, Eli Lilly's had a great year up 35% and really one of the leaders of that healthcare run.

As you mentioned, they've been able to capitalize on, you know, really the the biggest opportunity right now in healthcare with their three leading GLP1 products.

2026-11-12看涨
The Big 3: JNJ, LLY, AAPL
订阅或试用后可见这一步的正文
2026-10-29看涨
Thursday's First Moves: FTNT Falls After Earnings, CAT Tumbles, LLY Rises
订阅或试用后可见这一步的正文
2026-10-28看涨
Ghabour: Fed "Biggest Risk to Bull Market;" Bullish on MSFT, CRWD, LLY
订阅或试用后可见这一步的正文
2026-09-18
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"
订阅或试用后可见这一步的正文
2026-09-15看涨
Tuesday's First Moves: LLY & ETSY Upgrades, PLAY Plunges After Earnings
订阅或试用后可见这一步的正文
更早的 5 条正文需要订阅
最近 2 条的正文公开可读。更早的条目保留日期与方向,正文随订阅解锁。
订阅后阅读全部 5 条更早的观点